Please login to the form below

Not currently logged in
Email:
Password:

Large rise in pharma spend on apps and web

A report shows that in 2010 pharmaceutical companies increased their investment in digital, including mobile phone apps, social media and educational websites, by 78 per cent

Progressions: Building Pharma 3.0, a report published by Ernst & Young, shows that in 2010 pharmaceutical companies increased their investment in digital, including mobile phone apps, social media, educational websites and wireless devices, by 78 per cent. 

The report defines "Pharma 3.0" as a shift by the pharmaceutical industry from its traditional role of producing new medicine to the evolution of a new role demonstrating improvements in health outcomes and creating innovative new business models.

A substantial number of non-pharma companies have collaborated with industry on these initiatives. Data from the report estimates that at least $20bn has been invested in the Pharma 3.0 business model by non-pharma, in comparision to significantly lower financial input from the pharma companies themselves.

"New entrants to the healthcare industry are clearly committing much more to business model innovation than pharma companies," said Carolyn Buck Luce, global pharmaceutical leader at Ernst & Young. 

"The companies that succeed in this new healthcare ecosystem will do so by developing innovative outcomes-focused offerings through structured, systematic and scalable approaches to business model innovation. Just as importantly, pharma companies should demonstrate to new players in the healthcare space why the unique insights they can provide related to patient outcomes will make them indispensable partners."

A large proportion of pharma's 3.0 investments have been in mobile health technology – particularly smart phone apps. The report shows that by 2010, investment in mobile apps accounted for 50 per cent of all new initiatives, an increase of 34 per cent compared with the period 2006 to 2009.

The first mobile apps to be developed by pharma were mostly focussed on diabetes management. By 2010, smart phone apps from pharma were available in an estimated 14 disease areas with oncology represented more than any other area and accounting for 15 per cent of all initiatives.

The full report (pdf) is available from Ernst & Young.


17th February 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics